X-ray vendor Trex Medical (Hall A, #3500) has completed the clinical trials required for a regulatory submission of its full-field digital mammography detector and is planning to submit a 510(k) filing for the product some time around the RSNA show,
X-ray vendor Trex Medical (Hall A, #3500) has completed the clinical trials required for a regulatory submission of its full-field digital mammography detector and is planning to submit a 510(k) filing for the product some time around the RSNA show, according to Hal Kirshner, CEO and president of the Danbury, CT, company. Trex plans to offer the CCD-based detectors as retrofits to installed Lorad and Bennett mammography units.
Trex will display the latest clinical images acquired with the detectors at multicenter clinical trials used to support the FDA filing. In the trials, 520 patients were examined, and the studies were being read in the weeks up to the RSNA conference. Clinicians participating in the trials will also be present to discuss their findings.
Farther down the product pipeline are flat-panel digital detectors, which Trex will display in its RSNA booth as works-in-progress for general radiographic systems manufactured by its Bennett and Continental subsidiaries. In addition to static x-ray studies, Trex plans to develop versions for fluoroscopy and cardiac cath applications, and will show a demonstration of the panels used for 30 fps imaging.
The flat-panel devices are about a year from a regulatory submission, Kirshner said. Trex also plans to develop a flat-panel digital mammography detector, although that project is not as urgent because the company's CCD-based product is about to reach the market.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
Is the Kaiser Score More Effective than BI-RADS for Assessing Contrast-Enhanced Mammography and MRI?
October 14th 2024For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.
FDA Clears New Features in AI-Powered Mammography Software Suite
October 11th 2024Therapixel’s MammoScreen suite has received 510(k) FDA clearances for a breast density assessment feature and updated software that includes automated pre-reporting, which reportedly expedites reporting of mammography findings.